Study finds less expensive noninvasive test is an effective alternative for colorectal cancer screening

Commercially available noninvasive screening tests for colorectal cancer—a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard®)—are equally effective for screening patients with early-stage colorectal cancer. However, a FIT costs about one-fifth of the multi-target DNA test, according to new study results presented at the Scientific Forum of the American College of Surgeons (ACS) Clinical Congress 2022.

source https://medicalxpress.com/news/2022-10-expensive-noninvasive-effective-alternative-colorectal.html